Experimental shot aims to clear Hard-to-Treat HPV strains
NCT ID NCT07714577
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study tests an experimental injection called BBM-C101 in 200 people with persistent HPV16 or HPV18 infection and low-grade precancerous lesions of the cervix, vulva, vagina, or anus. Participants receive four shots under the skin over three weeks. The trial monitors safety and whether the infection clears over one year, with an additional year of follow-up.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental injection called BBM-C101, given as a series of four shots under the skin over three weeks
- What this could lead to
- If successful, this could offer a non-surgical treatment option for persistent HPV16/18 infections and low-grade precancerous lesions.
- What could go wrong
- This is an early exploratory trial with no control group, so results may not prove effectiveness. The treatment could cause side effects or fail to clear the infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 1 OR 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.